Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy
暂无分享,去创建一个
S Michiels | S Adams | S Loi | S. Loi | W. Symmans | S. Demaria | S. Adams | S. Michiels | R. Salgado | A. Vingiani | C. Castañeda | G. Curigliano | Joselyn Sanchez | M. Dieci | M. Castillo | S. Luen | W. Symmans | T. D’alfonso | E. Andreopoulou | E Andreopoulou | R. Gould | E. Cheng | G Curigliano | R Salgado | S Demaria | M V Dieci | A Vingiani | W F Symmans | S J Luen | R E Gould | C Castaneda | T D’Alfonso | J Sanchez | E Cheng | M Castillo | M. Dieci | J. Sanchez | Stefan Michiels | Miluska Castillo | Timothy D’alfonso | Eleni Andreopoulou | G. Curigliano | Roberto Salgado | A. Vingiani | Carlos A. Castaneda | Esther Cheng | Sandra Demaria
[1] T. Nielsen,et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] T. Nielsen,et al. Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. , 2017, Seminars in cancer biology.
[3] P. Fasching,et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. , 2018, The Lancet. Oncology.
[4] Sung-Bae Kim,et al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy , 2017, The New England journal of medicine.
[5] Chengzhong Ye,et al. Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis , 2018, Nature Medicine.
[6] Gideon Blumenthal,et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis , 2014, The Lancet.
[7] Jedd D. Wolchok,et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response , 2017, Nature.
[8] M. Fehlings,et al. Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates , 2018, Nature.
[9] Christos Hatzis,et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] K. Hirakawa,et al. Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes and residual cancer burden , 2017, BMC Cancer.
[12] M. Mathieu,et al. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. , 2014, Annals of Oncology.
[13] C. Sotiriou,et al. A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] Mei Liu,et al. Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.